HHS Opens Door to Six Peptides, Lifting Hims & Hers
HIMS has more than doubled off its 52-week low of $13.74.
Summary
HHS said Wednesday it will exercise enforcement discretion, letting compounding pharmacies make six unapproved peptides — BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 — while regulators decide on formal authorization. That is a direct tailwind for Hims & Hers, which bought a peptide facility in California last year and is one of the largest compounding operators. The stock rose on the news. The catch: the FDA's pharmacy compounding advisory committee met in July and did not recommend authorizing these molecules, so the window is temporary and depends on where regulators land. This follows the October 15 report that HHS had sent an interim access policy to OMB for review — the policy is now out.
At the time of this announcement, HIMS was trading at $29.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $13.74 to $49.17. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.